Aadi bioscience announces financial results for the second quarter of 2022 and provides corporate update

Fyarro® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022 precision 1 phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activation at major cancer centers and large community networks; preliminary data expected 1h23 conference call to be held today at 8:30 am edt los angeles , aug. 10, 2022 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today provided a corporate update and announced financial results for the second quarter of 2022. "we continue to progress in key areas after our first full quarter following fyarro's launch.
AADI Ratings Summary
AADI Quant Ranking